Drugs / CMVpp65 Specific T-cells
CMVpp65 Specific T-cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00611637 | Aug 2005 → Feb 2008 | disease related to hematopoietic stem cell transplant | H. Kim Lyerly | Terminated | No outcome recorded Stop: Enrollment |
| Phase 21 trial | ||||||
| Phase 2 | NCT02136797 | May 2014 → Feb 2024 | cytomegalovirus infection | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMV pp65 Specific T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00611637 ↗ |
| Known as | CMVpp65-CTL | “The T-cells to be infused will be selected from our bank of GMP grade CMVpp65-CTL.” NCT02136797 ↗ |
| Known as | CMVpp65-CTL T-cells | “CMVpp65-CTL T-cells” NCT02136797 ↗ |
| Modality | Cell therapy | “CMV specific, T cell adoptive immunotherapy” NCT00611637 ↗ |
| Route | Intravenous | “T-cells will be administered by bolus intravenous infusion.” NCT02136797 ↗ |